[SCHEDULE 13G/A] Kiora Pharmaceuticals, Inc. SEC Filing
Rosalind Advisors, Rosalind Master Fund L.P. and two affiliated portfolio managers report beneficial ownership of 464,676 shares of Kiora Pharmaceuticals represented by warrants, which the filing treats as issuable Common Stock. The reported position equals 9.9% of the class based on 3,433,491 shares reported by the issuer, and all four reporting persons show 0 sole voting or dispositive power and 464,676 shared voting and dispositive power.
The filing notes these are pre-funded warrants subject to a blocker provision that prevents exercise to the extent it would raise beneficial ownership above 9.99%, so the actual number of Common Shares the reporting persons may hold after applying the blockers is lower than the amounts reported. The reporting parties certify the holdings were acquired in the ordinary course of business and not to influence control of the issuer.
Rosalind Advisors, Rosalind Master Fund L.P. e due gestori di portafoglio affiliati dichiarano la titolarit脿 effettiva di 464.676 azioni di Kiora Pharmaceuticals rappresentate da warrant, che la comunicazione considera come azioni ordinarie sottostanti. La posizione indicata corrisponde al 9,9% della classe sulla base di 3.433.491 azioni segnalate dall'emittente, e tutti e quattro i soggetti segnalanti mostrano 0 poteri di voto o di disposizione esclusivi e 464.676 poteri di voto e di disposizione condivisi.
La comunicazione specifica che si tratta di warrant pre-finanziati soggetti a una clausola di blocco che impedisce l'esercizio nella misura in cui aumenterebbe la titolarit脿 effettiva oltre il 9,99%, pertanto il numero effettivo di azioni ordinarie che i soggetti segnalanti potrebbero detenere dopo l'applicazione dei blocchi 猫 inferiore a quanto riportato. Le parti segnalanti certificano che le partecipazioni sono state acquisite nell'ambito ordinario dell'attivit脿 e non al fine di influenzare il controllo dell'emittente.
Rosalind Advisors, Rosalind Master Fund L.P. y dos gestores de cartera afiliados informan la propiedad beneficiaria de 464.676 acciones de Kiora Pharmaceuticals representadas por warrants, que la presentaci贸n trata como acciones ordinarias susceptibles de emisi贸n. La posici贸n informada equivale al 9,9% de la clase seg煤n 3.433.491 acciones reportadas por el emisor, y las cuatro personas informantes muestran 0 poder exclusivo de voto o disposici贸n y 464.676 poderes de voto y de disposici贸n compartidos.
La presentaci贸n se帽ala que se trata de warrants prefinanciados sujetos a una cl谩usula de bloqueo que impide el ejercicio en la medida en que aumente la propiedad beneficiaria por encima del 9,99%, por lo que el n煤mero real de acciones ordinarias que las partes informantes podr铆an poseer tras aplicar los bloqueos es inferior a las cantidades declaradas. Las partes informantes certifican que las participaciones se adquirieron en el curso ordinario de sus actividades y no para influir en el control del emisor.
Rosalind Advisors, Rosalind Master Fund L.P. 氚� 霊� 氇呾潣 瓿勳棿 韽姼韽措Μ鞓� 毵る媹鞝�電� 氚滍枆鞚胳澊 氤错喌欤茧 臧勳＜頃橂姅 鞗岆煱韸�搿� 響滌嫓霅� Kiora Pharmaceuticals鞚� 464,676欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤搓碃頄堨姷雼堧嫟. 氤搓碃霅� 歆�攵勳潃 氚滍枆鞚胳澊 氤搓碃頃� 3,433,491欤茧ゼ 旮办鞙茧 韥措灅鞀れ潣 9.9%鞐� 頃措嫻頃橂┌, 雱� 氇呾潣 氤搓碃鞚胳潃 氇憪 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 0鞚搓碃 鞚橁舶甓� 氚� 觳橂秳甓� 瓿惦彊 氤挫湢 464,676鞙茧 旮办灛霅橃柎 鞛堨姷雼堧嫟.
氤搓碃靹滌棎電� 頃措嫻 鞗岆煱韸戈皜 頄夓偓霅� 瓴届毎 鞁れ 靻岇湢歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅 彀嫧 臁绊暛(blocker provision)鞚� 鞝侅毄霅橂姅 靹犽秷順�(pre-funded) 鞗岆煱韸胳瀯鞚� 氇呾嫓霅橃柎 鞛堨柎, 彀嫧 臁瓣贝鞚� 鞝侅毄頃� 頉� 氤搓碃鞚鸽摛鞚� 鞁れ牅搿� 氤挫湢頃� 靾� 鞛堧姅 氤错喌欤检潣 靾橂姅 氤搓碃霅� 靾橂炒雼� 鞝侅潉 靾� 鞛堨姷雼堧嫟. 氤搓碃 雼轨偓鞛愲摛鞚� 氤挫湢 歆�攵勳澊 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚半牓鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Rosalind Advisors, Rosalind Master Fund L.P. et deux g茅rants de portefeuille affili茅s d茅clarent la propri茅t茅 b茅n茅ficiaire de 464鈥�676 actions de Kiora Pharmaceuticals repr茅sent茅es par des warrants, que le d茅p么t consid猫re comme des actions ordinaires susceptibles d'锚tre 茅mises. La position d茅clar茅e 茅quivaut 脿 9,9鈥�% de la cat茅gorie sur la base de 3鈥�433鈥�491 actions signal茅es par l'茅metteur, et les quatre d茅clarants indiquent 0 pouvoir de vote ou de disposition exclusif et 464鈥�676 pouvoir(s) de vote et de disposition partag茅(s).
Le d茅p么t pr茅cise qu'il s'agit de warrants pr茅financ茅s soumis 脿 une clause de blocage emp锚chant l'exercice dans la mesure o霉 il ferait d茅passer la propri茅t茅 b茅n茅ficiaire au-del脿 de 9,99鈥�%, de sorte que le nombre r茅el d'actions ordinaires que les d茅clarants pourraient d茅tenir apr猫s application des bloqueurs est inf茅rieur aux montants d茅clar茅s. Les parties d茅clarantes certifient que les participations ont 茅t茅 acquises dans le cours normal de leurs activit茅s et non dans le but d'influencer le contr么le de l'茅metteur.
Rosalind Advisors, Rosalind Master Fund L.P. und zwei angeschlossene Portfoliomanager melden das wirtschaftliche Eigentum an 464.676 Aktien von Kiora Pharmaceuticals, die durch Warrants dargestellt werden und in der Meldung als ausgebbare Stammaktien behandelt werden. Die gemeldete Position entspricht 9,9% der Klasse basierend auf 3.433.491 vom Emittenten gemeldeten Aktien, und alle vier Melder weisen 0 alleiniges Stimm- oder Verf眉gungsrecht sowie 464.676 geteilte Stimm- und Verf眉gungsrechte aus.
In der Meldung wird darauf hingewiesen, dass es sich um vorfinanzierte Warrants handelt, die einer Blocker-Regelung unterliegen, die die Aus眉bung verhindert, soweit sie das wirtschaftliche Eigentum 眉ber 9,99% erh枚hen w眉rde. Daher ist die tats盲chliche Anzahl der Stammaktien, die die meldenden Personen nach Anwendung der Blocker halten k枚nnten, niedriger als angegeben. Die meldenden Parteien best盲tigen, dass die Best盲nde im normalen Gesch盲ftsverlauf erworben wurden und nicht dazu dienen, die Kontrolle 眉ber den Emittenten zu beeinflussen.
- Material economic stake disclosed: The reporting group holds 464,676 warrants representing a 9.9% position of the class, which signals significant investor interest.
- Ordinary-course certification: Reporting parties certify the securities were acquired and are held in the ordinary course of business and not to influence control.
- Holdings are warrants, not current common stock: The position does not represent immediate voting control or ownership of outstanding shares.
- Blocker provision limits exercise: Pre-funded warrant terms prevent exercise to the extent it would raise ownership above 9.99%, reducing the potential for immediate influence or conversion.
Insights
TL;DR: A sizeable economic position (9.9%) is held via warrants, limiting immediate voting control and creating potential future dilution.
The filing discloses a material position equal to 9.9% of outstanding common stock, but the stake is composed of warrants, not presently outstanding common shares. Sole voting and dispositive power are reported as zero, indicating no direct control today. The presence of a blocker provision preventing exercise above 9.99% reduces the likelihood of immediate conversion to voting stock. For investors, this is a notable passive economic exposure rather than an active governance event.
TL;DR: Holders disclaim control and certify ordinary-course intent; governance influence appears limited by shared power and blocker terms.
The reporting entities and individuals explicitly disclaim beneficial ownership beyond the warrants and assert the securities were not acquired to influence control. With 0 sole voting or dispositive power and only shared power tied to the warrants, the filing indicates limited present ability to direct corporate actions. The blocker on pre-funded warrants further constrains any conversion that would exceed the 9.99% threshold, keeping immediate governance impact low.
Rosalind Advisors, Rosalind Master Fund L.P. e due gestori di portafoglio affiliati dichiarano la titolarit脿 effettiva di 464.676 azioni di Kiora Pharmaceuticals rappresentate da warrant, che la comunicazione considera come azioni ordinarie sottostanti. La posizione indicata corrisponde al 9,9% della classe sulla base di 3.433.491 azioni segnalate dall'emittente, e tutti e quattro i soggetti segnalanti mostrano 0 poteri di voto o di disposizione esclusivi e 464.676 poteri di voto e di disposizione condivisi.
La comunicazione specifica che si tratta di warrant pre-finanziati soggetti a una clausola di blocco che impedisce l'esercizio nella misura in cui aumenterebbe la titolarit脿 effettiva oltre il 9,99%, pertanto il numero effettivo di azioni ordinarie che i soggetti segnalanti potrebbero detenere dopo l'applicazione dei blocchi 猫 inferiore a quanto riportato. Le parti segnalanti certificano che le partecipazioni sono state acquisite nell'ambito ordinario dell'attivit脿 e non al fine di influenzare il controllo dell'emittente.
Rosalind Advisors, Rosalind Master Fund L.P. y dos gestores de cartera afiliados informan la propiedad beneficiaria de 464.676 acciones de Kiora Pharmaceuticals representadas por warrants, que la presentaci贸n trata como acciones ordinarias susceptibles de emisi贸n. La posici贸n informada equivale al 9,9% de la clase seg煤n 3.433.491 acciones reportadas por el emisor, y las cuatro personas informantes muestran 0 poder exclusivo de voto o disposici贸n y 464.676 poderes de voto y de disposici贸n compartidos.
La presentaci贸n se帽ala que se trata de warrants prefinanciados sujetos a una cl谩usula de bloqueo que impide el ejercicio en la medida en que aumente la propiedad beneficiaria por encima del 9,99%, por lo que el n煤mero real de acciones ordinarias que las partes informantes podr铆an poseer tras aplicar los bloqueos es inferior a las cantidades declaradas. Las partes informantes certifican que las participaciones se adquirieron en el curso ordinario de sus actividades y no para influir en el control del emisor.
Rosalind Advisors, Rosalind Master Fund L.P. 氚� 霊� 氇呾潣 瓿勳棿 韽姼韽措Μ鞓� 毵る媹鞝�電� 氚滍枆鞚胳澊 氤错喌欤茧 臧勳＜頃橂姅 鞗岆煱韸�搿� 響滌嫓霅� Kiora Pharmaceuticals鞚� 464,676欤检棎 雽�頃� 鞁れ鞝� 靻岇湢甓岇潉 氤搓碃頄堨姷雼堧嫟. 氤搓碃霅� 歆�攵勳潃 氚滍枆鞚胳澊 氤搓碃頃� 3,433,491欤茧ゼ 旮办鞙茧 韥措灅鞀れ潣 9.9%鞐� 頃措嫻頃橂┌, 雱� 氇呾潣 氤搓碃鞚胳潃 氇憪 雼弲 鞚橁舶甓� 霕愲姅 觳橂秳甓� 0鞚搓碃 鞚橁舶甓� 氚� 觳橂秳甓� 瓿惦彊 氤挫湢 464,676鞙茧 旮办灛霅橃柎 鞛堨姷雼堧嫟.
氤搓碃靹滌棎電� 頃措嫻 鞗岆煱韸戈皜 頄夓偓霅� 瓴届毎 鞁れ 靻岇湢歆�攵勳澊 9.99%毳� 齑堦臣頃橃 鞎婋弰搿� 頃橂姅 彀嫧 臁绊暛(blocker provision)鞚� 鞝侅毄霅橂姅 靹犽秷順�(pre-funded) 鞗岆煱韸胳瀯鞚� 氇呾嫓霅橃柎 鞛堨柎, 彀嫧 臁瓣贝鞚� 鞝侅毄頃� 頉� 氤搓碃鞚鸽摛鞚� 鞁れ牅搿� 氤挫湢頃� 靾� 鞛堧姅 氤错喌欤检潣 靾橂姅 氤搓碃霅� 靾橂炒雼� 鞝侅潉 靾� 鞛堨姷雼堧嫟. 氤搓碃 雼轨偓鞛愲摛鞚� 氤挫湢 歆�攵勳澊 鞓侅梾 瓿检爼鞐愳劀 旆摑霅橃棃鞙茧┌ 氚滍枆鞚胳潣 歆�氚半牓鞐� 鞓來枼鞚� 氙胳箻旮� 鞙勴暅 瓴冹澊 鞎勲嫎鞚� 歃濍獏頃╇媹雼�.
Rosalind Advisors, Rosalind Master Fund L.P. et deux g茅rants de portefeuille affili茅s d茅clarent la propri茅t茅 b茅n茅ficiaire de 464鈥�676 actions de Kiora Pharmaceuticals repr茅sent茅es par des warrants, que le d茅p么t consid猫re comme des actions ordinaires susceptibles d'锚tre 茅mises. La position d茅clar茅e 茅quivaut 脿 9,9鈥�% de la cat茅gorie sur la base de 3鈥�433鈥�491 actions signal茅es par l'茅metteur, et les quatre d茅clarants indiquent 0 pouvoir de vote ou de disposition exclusif et 464鈥�676 pouvoir(s) de vote et de disposition partag茅(s).
Le d茅p么t pr茅cise qu'il s'agit de warrants pr茅financ茅s soumis 脿 une clause de blocage emp锚chant l'exercice dans la mesure o霉 il ferait d茅passer la propri茅t茅 b茅n茅ficiaire au-del脿 de 9,99鈥�%, de sorte que le nombre r茅el d'actions ordinaires que les d茅clarants pourraient d茅tenir apr猫s application des bloqueurs est inf茅rieur aux montants d茅clar茅s. Les parties d茅clarantes certifient que les participations ont 茅t茅 acquises dans le cours normal de leurs activit茅s et non dans le but d'influencer le contr么le de l'茅metteur.
Rosalind Advisors, Rosalind Master Fund L.P. und zwei angeschlossene Portfoliomanager melden das wirtschaftliche Eigentum an 464.676 Aktien von Kiora Pharmaceuticals, die durch Warrants dargestellt werden und in der Meldung als ausgebbare Stammaktien behandelt werden. Die gemeldete Position entspricht 9,9% der Klasse basierend auf 3.433.491 vom Emittenten gemeldeten Aktien, und alle vier Melder weisen 0 alleiniges Stimm- oder Verf眉gungsrecht sowie 464.676 geteilte Stimm- und Verf眉gungsrechte aus.
In der Meldung wird darauf hingewiesen, dass es sich um vorfinanzierte Warrants handelt, die einer Blocker-Regelung unterliegen, die die Aus眉bung verhindert, soweit sie das wirtschaftliche Eigentum 眉ber 9,99% erh枚hen w眉rde. Daher ist die tats盲chliche Anzahl der Stammaktien, die die meldenden Personen nach Anwendung der Blocker halten k枚nnten, niedriger als angegeben. Die meldenden Parteien best盲tigen, dass die Best盲nde im normalen Gesch盲ftsverlauf erworben wurden und nicht dazu dienen, die Kontrolle 眉ber den Emittenten zu beeinflussen.
FAQ
How many KPRX shares are reported as beneficially owned?
What percentage of KPRX does the reported position represent?
Do the reporting persons have voting or dispositive power over these KPRX securities?
Are these common shares or warrants for KPRX?
Can the reporting parties immediately convert to more than 9.99% ownership?
